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p53has been shown to be one of the most frequently mutated genes
in human cancers (Lane and Benchimol, 1990; Vogelstein, 1990).
Several studies have shown that mutations of the p53gene in both
acute myeloblastic leukaemia (AML) and acute lymphoblastic
leukaemia (ALL) are relatively infrequent in contrast to solid
tumours where point mutations are common. Although p53muta-
tions are common in AML cell lines (Sugimoto et al, 1992), the
reported frequency in primary AML cases is much lower (5—10%)
(Slingerland et al, 1991; Fenaux et al, 1992a; Hu et al, 1992). The
incidence of p53mutations in AML is higher with presence of
monosomy 17p (Fenaux et al, 1991). In addition, AML arising
secondary to previous chemotherapy has a high incidence of p53
mutations (Ben-Yehuda et al, 1996). In ALL, a low incidence of
p53mutations has been reported (Wada et al, 1993): thus in a large
study of 330 patients with paediatric ALL at diagnosis only eight
patients with mutations were detected. These observations have led
to the suggestion that p53mutations are of less significance in acute
leukaemia compared to other tumours. However, evidence to the
contrary has come from a number of reports. Firstly AML associ-
ated with p53mutations has a very poor prognosis with a low
complete remission rate and a poor survival (Wattel et al, 1994).
Secondly in T-ALL the incidence of p53 mutations was found to
occur at a much higher frequency in leukaemic cells at relapse
(24% of cases) compared to patients studied at presentation where
p53mutations are rare (Jonveaux et al, 1991; Mori et al, 1992;
Diccianni et al, 1994; Hsiao et al, 1994). These latter findings could
be interpreted as indicating that p53mutations are associated with
clonal evolution in acute leukaemia and are therefore a ￿late￿ event,
as in chronic myeloid leukaemia (Nakai et al, 1993). An alternative
explanation for the findings in T-ALL is that the mutation is present
at presentation but only in a minor subclone which is able to
survive remission induction and consolidation chemotherapy,
mediating disease relapse. This possibility is supported by data
from Wada et al (1994) who identified p53mutations in cell lines
established from patients with relapsed leukaemia. In none of the
cases could they identify the mutation in presentation samples
using single-strand conformation polymorphism (SSCP) analysis.
However, using the more sensitive technique of allele-specific PCR
they were able to identify a mutated subpopulation accounting for
between 0.01% and 1% of presentation cells.
To gain further insight into the role of p53mutation in the
evolution of acute leukaemia, we have studied the structure of the
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Correspondence to:NH Russellp53gene in leukaemic cells from a series of patients at relapse by
direct sequencing of exons 5—9. We detected a p53mutation in
four out of 14 (28.6%) patients with ALL suggesting that muta-
tions of p53are much more frequently detected in relapsed
samples than at presentation. However, in all cases the mutation
could be detected at presentation in a minority subclone either by
direct sequencing or by allele-specific PCR.
MATERIALS AND METHODS
Patients
Bone marrow samples from 55 patients with relapsed acute
leukaemia were analysed including 41 AML (median age 49
years; range 21—80 years) and 14 B-lineage ALL (median age 29
years; range 3—54 years) patients. Samples had been previously
cryopreserved in 10% dimethyl sulphoxide (DMSO) in a
controlled-rate freezer. All patients had achieved a complete
remission having received treatment with intensive chemotherapy
according to the Medical Research Council trials of AML-9 or
AML-10 for patients with AML or UKALL-10, UKALLXa or
UKALL-12 for patients with ALL.
Primers for exon 5–9 of p53
Oligonucleotide primers for the PCR and sequence reactions were
purchased from R&D Systems Europe Ltd (Abingdon, UK). The








The sizes of PCR products were: 406bp for exon 5—6, 148bp
for exon 7 and 324bp for exon 8—9.
PCR and direct sequencing analysis
High molecular weight DNA was prepared from cryopreserved
peripheral blood or bone marrow cells from patients at relapse.
DNA was extracted by a DNA extraction kit (Stratagene, La Jolla,
CA, USA) following the manufacturer￿s instructions.
PCR reaction was carried out in a 50ml volume including 1mM
magnesium chloride, 0.12mMof each dNTP, 1 ´buffer (20mM
Tris-HCl pH 8.4, 50mMpotassium chloride), 200ng of genomic
DNA, 1U of Taqpolymerase (Promega, Madison, WI, USA) and
1mMof both the upstream and downstream PCR primers.
Amplification was carried out in Techne Thermal Cycler, PHC-3
after an initial denaturation at 94°C for 3min. A total of 35 cycles
were performed using the following temperature and time profile:
denaturation at 94°C for 1min; primer annealing at 55°C (for exon
5—6), 62°C (for exon 7) and 57°C (for exon 8—9) for 1min; primer
extension at 72°C for 1min; and a final extension of 72°C for
5min. The PCR products were purified by Chroma SpinTM
Columns (Clontech, Palo Alto, CA, USA). The PCR products for
exon 7 were purified by Chroma Spin-100. The PCR products for
exon 5—6 and exon 8—9 were purified by Chroma Spin-200.
The PCR products were sequenced by both forward and reverse
primers in each sample. About 80ng of purified PCR products for
exon 7, and 180ng of purified PCR products for exon 5—6 and exon
8—9 were added to the sequencing reaction. The final reaction
volumes were 20ml also including 8.0ml of Terminator Ready
Reaction Mix (Perkin Elmer, Foster City, CA, USA), 3.2pmol of
forward or reverse primer and dH2O. The cycle sequencing was
performed for 25 cycles in PTC-100TM Programmable Thermal
Controller (MJ Research Inc, Watertown, MA, USA) as following
programme: 96°C for 30s, 50°C for 15s and 60°C for 4min. The
extension products were purified by an ethanol precipitation
protocol. The dried pellets were dissolved in 6ml of loading buffer
by combining 5ml of deionized formamide and 1ml of 25mM
EDTA (pH 8.0) containing 50mg ml—1 of blue dextran. The
samples were vortexed and heated to 90°C for 2min to denature,
then cooled on ice until ready to load. Samples (1.5ml) were then
loaded to a 4.2% polyacrylamide gel containing 8.3Murea. The
sequence analysis was performed on a 377 automated DNA
sequencer (PE Applied Biosystems, Foster City, CA, USA). Where
a mutation was detected this was confirmed on a second occasion
by a separate PCR reaction and repeat sequencing.
Demonstration of mutant p53 at presentation by
allele-specific gene amplification
As the failure to detect p53mutations in presentation samples
might reflect the lack of sensitivity of direct sequencing to detect
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Table 1Clinical characteristics of patients with p53 mutations at relapse
Mutated p53 gene
Patients Diagnosis Sex/age Cytogenetics Exon Codon Nucleotide Amino acid
(FAB type) change change
1. BHM c-ALL M/3 46 XY, –4, –12p, +14, +21 5 175 CGC®CAC Arg®His
2. GD AML (M4) F/58 47 XX, +8 8 273 CGT®TGT Arg®Cys
3. IR ALL (B) F/25 46 XX, t(8;14) 6 193 CAT®CGT His®Arg
4. SR AML (M1) M/55 46 XY, –4q, –7q, –7, –21 7 241 TCC®TGC Ser®Cys
5. WG ALL (pre-B) F/17 47 X, –X, –4, –6(q2), +13, +13, +14,  6 209 AGA®ACA Arg®Thr
–20 +mar
6. WN c-ALL M/32 46 XY 5 175 CGC®TGC Arg®Cys
7. WS AML (M6) F/32 43 XX, –5, –7, –18, –22, +12p 7 248 CGG®TGG Arg®Thr
ALL, acute lymphoblastic leukaemia; AML, acute myeloblastic leukaemia.the presence of a minority clone, we proceeded to use allele-
specific PCR to re-analyse the presentation sample in two patients
(BHM and WG) where we had failed to detect the mutation by
sequencing. The allele-specific primer was so designed that they
differed from the normal allele in that their terminal 3¢ nucleotide
was underlined in the nucleotide sequence as following: 5¢-
ATGACGGAGGTTGTGAGGCA-3¢ (for BHM); 5¢-CACTAT-
GTCGAAAAGTGTTTG-3¢ (for WG). The conditions of the PCR
reaction were similar to that described earlier except that the
annealing temperature was 68°C (for BHM) and 65°C (for WG).
The expected size of PCR product was 264 bp (for BHM) and
369 bp (for WG).
IgH FR1 fingerprinting
The fingerprinting test was carried out in patient BHM according
to a previously described method (Chim et al, 1996). Briefly, the
FR1 primers (VH3, VH4a and VH4b) were used in combination
with the JH primer in a 20 ml final volume of PCR reaction
including a-32p dCTP. After 25 cycles of PCR (94°C for 1 min,
54°C for 1 min and 72°C for 1 min each cycle), the products were
denatured by boiling and loaded onto a sequencing acrylamide gel
(6% acrylamide and 8 M urea). The gel was run at 30 W for 2.5 h at
room temperature in 0.5 ´ TBE, then was transferred to a sheet of
3 MM Whatman paper, and dried at 80°C. Autoradiography was
carried out at — 70°C for about 24 h with an intensifying screen.
RESULTS
Of the 55 patients with relapsed acute leukaemia analysed by
direct sequencing of exons 5—9, p53 mutations were detected in a
total of seven (12.7%). This consisted of four out of 14 (28.6%)
patients with ALL but only three of 41 (7.1%) patients with AML.
Clinical and cytogenetic data of the patients with p53 mutation at
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Figure 1 Comparisons of p53 mutations detected by direct sequencing at presentation (left) and at relapse (right) of three ALL patients: BHM (top), IR (middle)
and WG (bottom). A CGC®CAC transition occurred in codon 175, resulted in Arg®His substitution (BHM). A CAT®CGT transition in codon 193, resulted in a
His®Arg substitution in patient IR. An AGA®ACA transversion in codon 209, resulted in an Arg®Thr substitution in patient WG. Analysis of the presentation
samples confirmed the presence of the mutation in IR, but not in BHM or WGrelapse are shown in the Table 1. The mutations of the p53 gene in
ALL occurred at exon 5 in two cases (BHM, WN) and at exon 6 in
two cases (IR, WG); in AML the mutations of p53 occurred at
exon 7 in two cases (SR, WS) and at exon 8 in one case (GD). All
of these mutations were missense mutations and were confirmed
by sequencing with reverse primers. Identical mutations at codon
175 (G®A) (Wada et al, 1993), 193 (Fenaux et al, 1992b; Baldini
et al, 1994), 248 (Abo et al, 1993; Trecca et al, 1994) and 273
(Gaidano et al, 1991; Fenaux et al, 1992a; 1992b; Nishimura et al,
1995) have been previously reported in leukaemia, but the
mutations at codons 175 (C®T), 209 and 241 have only been
previously reported in solid tumours.
Analysis of p53 mutations in presentation samples of
patients with mutation at relapse
Part of the purpose of this study was to determine if mutations
detected at relapse of acute leukaemia were present in presentation
samples. Cryopreserved samples from presentation material were
available for analysis in three (BHM, IR and WG) of the four ALL
cases and in two (GD and WS) of the three AML cases. The pres-
ence of p53 mutations at presentation was initially studied by direct
sequencing of the PCR-amplified exon mutated in the relapse
sample. The results for the ALL patients are shown in Figure 1, the
identical mutation was detected at presentation in one sample (IR),
however as can be seen the mutation was present in a smaller
proportion of cells and the majority expressed wild-type sequences.
No mutation was detected at presentation in BHM or WG. In both
AML patients, the identical mutation was present in the presenta-
tion samples using direct sequencing as shown in Figure 2.
Presence of mutant p53 at presentation by
allele-specific gene amplification
The reported sensitivity of automated direct sequencing or SSCP
to detect a mutated population in the presence of wild-type
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Figure 2 Comparisons of p53 mutations detected by direct sequencing at presentation (left) and at relapse (right) of two AML patients: GD (top) and WS
(bottom). A CGT®TGT transition occurred in codon 273, resulted in Arg®Cys substitution (GD). A CGG®TGG transition in codon 248, resulted in an Arg®Thr








Figure 3 Allele-specific DNA amplifications in patient WG and BHM. 200 ng
of DNA was used in the 35 cycles of PCR in each reaction. The PCR bands
of mutant p53 (369 bp) were shown in both relapse (lane B) and presentation
(lane C) samples of patient (WG) and the PCR bands of mutant p53 (264 bp)
were shown in both relapse (lane E) and presentation (lane F) samples of
patient (BHM), although the bands in presentations were much weaker than
those in relapse, and the mutant bands were confirmed by direct sequencing.
No bands were amplified in a further patient (SJ) as a negative control (lane
D and lane G). Lane 1 was 50 bp ladder as markersequences is only about 10% (Gaidano et al, 1991; Murakami et al,
1991; Larder et al, 1993). As a consequence the failure to detect
p53 mutations in presentation samples of patients BHM and WG
might reflect a lack of sensitivity of direct sequencing to detect the
presence of a minor clone (< 10% of cells) carrying p53 mutations.
We proceeded to use allele-specific PCR, a far more sensitive
method capable of detecting mutated cells with a sensitivity of at
least 1 in 104 (Wada et al, 1994), to re-analyse the presentation
sample in patients WG and BHM. As shown in Figure 3, the allele-
specific oligonucleotides amplified a PCR product with the
predicted size (264 bp and 369 bp for BHM and WG, respectively)
in both the relapsed and the presentation samples, although the
bands in the presentation samples were weaker than those at
relapse. The percentage of blasts in the relapsed and presentation
samples in both these cases was > 90%. The bands in the presenta-
tion samples were purified and sequenced, the sequence result
confirming that those were mutated from the gene p53. No positive
signals were observed using the same primers with DNA from a
negative control sample (SJ), in which we had previously estab-
lished that codon 175 and codon 209 were normal.
Clonality of the B-cells in ALL patient BHM
As part of a separate study (Papaioannou et al, 1997), clonality of
the B cells from patient BHM were further investigated by IgH
FR1 fingerprinting. At presentation a major VH3 clone was
detected with minor VH4a and VH4b being present. However, at
relapse (39 months later) the VH4b clone almost entirely replaced
the VH3, which was undetectable as shown in Figure 4.
DISCUSSION
p53 mutations are frequently observed in solid tumours, and in a
number of haematological malignancies including chronic myeloid
leukaemia and follicular lymphoma where the acquisition of p53
mutation is associated with disease progression and transformation
to high grade disease (Ahuja et al, 1989; Lo Coco et al, 1993;
Sander et al, 1993). In acute leukaemia, however, the incidence is
low, thus Fenaux et al (1992a; 1992b) reported that only one of 50
cases of pre-B ALL and eight out of 112 cases of AML had a
demonstrable p53 mutation. Likewise, Wada et al (1993) found an
incidence of p53 mutations of only 2—3% in a large series of
patients with pre-B ALL. Indeed the low incidence of p53 mutation
in childhood ALL has been put forward as an explanation for the
high degree of chemosensitivity of this tumour (Lowe et al, 1993).
As with current treatment protocols, approximately 50% of
adult patients with AML or ALL will relapse after achieving CR
and as p53 mutations might be expected to be associated with a
poor response to therapy we decided to analyse samples from
relapsed patients for the presence of p53 mutations in exons 5—9 in
order to establish whether the biological significance of p53 muta-
tion in the evolution of acute leukaemia had been underestimated
by analysing presentation samples. The majority of patients
studied had been entered into UK Medical Research Council trials
for the treatment of AML or ALL and all had received aggressive
chemotherapy and we took care to exclude any patients with
secondary AML or antecedent myelodysplasia who might be more
likely to have p53 mutations (Sugimoto et al, 1993). SSCP is the
most commonly used method for detection of p53 mutations with a
sensitivity for detecting mutated cells in the presence of wild-type
sequence of about 10% (Gaidano et al, 1991; Murakami et al,
1991; Larder et al, 1993). However SSCP may also miss p53
mutations due to lack of conformational change and therefore the
use of SSCP as a screening assay may underestimate the frequency
of mutations (Martincic and Whitlock, 1996). For this study we
therefore decided to directly sequence exon 5—9 of all relapsed
samples. We found a higher incidence of p53 mutations in relapsed
samples than has been reported for ALL at presentation. Overall,
four out of 14 ALL patients (28.6%) had a p53 mutation at relapse
which compared with just three out of 41 AML patients (7.3%), an
incidence comparable to that reported for AML at presentation.
Our results in ALL are comparable to those reported for relapsed
T-ALL by Diccianni et al (1994). All of the ALL mutations were
missense mutations, two of them in codon 175, which is a frequent
site of p53 mutation. In three of the four ALL patients presentation
samples were available for analysis, which confirmed the presence
of the mutation by direct sequencing in one case. This patient had
B-ALL, which is known to be associated with a higher incidence
Mechanisms of relapse in acute leukaemia 1155
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Figure 4 Clonality of the B-cells was analysed in the presentation (Pros.)
and relapse (Rel.) material of BHM by IgH fingerprinting test with
combination of primers JH and VH3, or VH4a or VH4b. A major VH3 clone
and minor VH4a and VH4b were detected in the presentation (black arrows).
However, a major VH4b clone and minor VH4a clone, but not VH3 clone
were detected at relapse. Amplification of presentation and relapse DNA by
using VH4b (sense primer) and allele-specific oligonucleotides (antisense
primer) clearly indicated the identity of the VH4b clone by ethidium bromide
gel electrophoresis as shown in the bottom of the figure (left lane: DNA
marker, middle lane: presentation sample, right lane: relapse sample)of p53 mutation than other types of ALL (Gaidano et al, 1991). By
direct sequencing, presentation samples from the other two ALL
patients showed no detectable mutation but using allele-specific
PCR with appropriate controls, a band was amplified at both
presentation and relapse in both cases. It is interesting that one of
those patients was investigated by IgH fingerprinting and a VH4
rearrangement present in only a minor subclone at presentation
was the predominant clone at relapse; one might speculate that the
VH4 subclone also harboured the p53 mutation present at relapse.
These observations suggest that in ALL, cells carrying p53 muta-
tions are present early in the natural history of the disease in some
patients but our studies only allow a crude estimate of the size of
this population (0.01—10%). Resistance to chemotherapy-induced
apoptosis may confer a survival advantage to a p53-mutated
subclone which by clonal expansion could mediate relapse. This
may be of biological importance in ALL where previous studies
have demonstrated oligoclonality in 25—30% of cases at diagnosis
(Beishuizen et al, 1991; Coyle et al, 1996). We did not find a
higher incidence of p53 mutations at relapse of AML. However,
this does not mean that p53-mutated subclones do not mediate
relapse in AML as one of the patients studied by Wada et al (1994)
had AML. The kinetics of a relapse will depend upon the size of
the mutated clone at presentation and other biological variables.
Our results may indicate that p53 mutations are a determinant of
outcome in both adults and children with ALL being implicated in
both primary treatment failure as well as relapse in a proportion of
patients (Diccianni et al, 1994; Marks et al, 1996). It would be of
interest to confirm these results on a larger series of patients in a
prospective manner. The development of new techniques to detect
p53 mutations in a small clone of leukaemic cells at presentation,
which are not dependent upon prior knowledge of the sequence,
may be of value in identifying patients with a high risk of disease
recurrence.
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